Page last updated: 2024-09-05

olpadronic acid and Cancer of Prostate

olpadronic acid has been researched along with Cancer of Prostate in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hillegonds, DJ; Hoffman, RM; Yang, M	1
Hamdy, NA; Lycklama à Nijeholt, AA; Papapoulos, SE; Pelger, RC; Zwinderman, AH	1
Berenson, J; Hortobagyi, G; Lipton, A; Major, PP	1
Arndt, JW; Hamdy, NA; Lycklama à Nijeholt, GA; Papapoulos, SE; Pelger, RC; Soerdjbalie-Maikoe, V; Zwinderman, AH	1

Reviews

1 review(s) available for olpadronic acid and Cancer of Prostate

Article	Year
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2000

Article

Year

Oral bisphosphonates: A review of clinical use in patients with bone metastases.

Cancer, 2000, Jan-01, Volume: 88, Issue:1

Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid

2000

Trials

1 trial(s) available for olpadronic acid and Cancer of Prostate

Article	Year
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone, 1998, Volume: 22, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Follow-Up Studies; Humans; Hydroxyproline; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Osteoblasts; Pain; Prostatic Neoplasms	1998

Article

Year

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.

Bone, 1998, Volume: 22, Issue:4

Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Follow-Up Studies; Humans; Hydroxyproline; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Osteoblasts; Pain; Prostatic Neoplasms

1998

Other Studies

2 other study(ies) available for olpadronic acid and Cancer of Prostate

Article	Year
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays	2006
Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:4 Topics: Aged; Combined Modality Therapy; Diphosphonates; Humans; Lumbar Vertebrae; Male; Pain; Palliative Care; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Spinal Neoplasms; Strontium; Thoracic Vertebrae; Treatment Outcome	2002

Article

Year

The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8

Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Disease Progression; Glycoproteins; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Osteoprotegerin; Pamidronate; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays

2006

Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.

European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:4

Topics: Aged; Combined Modality Therapy; Diphosphonates; Humans; Lumbar Vertebrae; Male; Pain; Palliative Care; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Spinal Neoplasms; Strontium; Thoracic Vertebrae; Treatment Outcome

2002